UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced it has been awarded a contract to advance the development of a cocktail of anti-botulinum neurotoxin monoclonal antibodies (mAb) by the Department of Defense (DOD) through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The contract ceiling value is $42.6 million.
“This contract is an important milestone for both Ology Bioservices and the DOD,” said Peter H. Khoury, Ph.D., president and CEO of Ology Bioservices. “Monoclonal antibodies represent an important, innovative option in medical countermeasure development, allowing the DOD to more effectively layer CBRN defense. We are excited to bring this next generation of countermeasures to the clinic.”Learn more about Department of Defense Awards Ology Bioservices Contract to Advance Anti-Botulinum Neurotoxin Monoclonal Antibodies.